> 2004 Publications
1.
A telomerase-immortalized primary human prostate cancer
clonal cell line with neoplastic phenotypes.
Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava
S, Arnstein P, Rhim JS.
Int J Oncol. 2004 Oct;25(4):1057-64.
Abstract
2.
Elevated expression of PCGEM1, a prostate-specific gene
with cell growth promoting function, is associated with high-risk
prostate cancer patients.
Petrovics G, Zhang W, Makarem M, Street JP, Connelly RR, Sun
L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S.
Oncogene, 23:605-611, 2004.
Abstract
| 
PDF
3.
Eligibility and outcomes reporting guidelines for
clinical trials for patients in the state of a rising prostate-specific
antigen: Recommendations from the prostate-specific antigen
working group.
Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small
EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci
MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak
D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis
C, and Soule HR:
J Clin Oncol, 22(3):537-56, 2004.
Abstract
|
PDF
4.
Early versus delayed hormonal therapy for prostate specific
antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda
L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl
D:
J Urol, 171:1141-47, 2004.
Abstract
5. Race/Ethnicity and the intensity of medical monitoring
under “watchful waiting” for prostate cancer.
Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis WW, Moul
JW, Fahey A:
Medical Care, 42:239-50, 2004.
Abstract
|
PDF
6. Race/Ethnicity and the receipt of watchful waiting
for the initial management of prostate cancer.
Shavers VL, Brown M, Potosky AL, Klabunde CN, Davis WW, Moul
JW, Fahey A:
J Gen Intern Med, 19:146-55, 2004.
Abstract
7.
External beam radiation therapy after radical prostatectomy:
efficacy and impact on urinary continence.
Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith
CV, Connelly RR, McLeod DG, Moul JW:
PCPD, 7:170-177, 2004.
Abstract
|
PDF
8.
Intermediate end point for prostate cancer-specific
mortality following salvage hormonal therapy for prostate-specific
antigen failure.
D’Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck
D, Renshaw AA, Loffredo M, Chen MH:
J Natl Cancer Inst, 96:509-15, 2004.
Abstract
|
PDF
9.
The economic burden of metastatic and prostate specific
antigen progression in patients with prostate cancer: findings
from a retrospective analysis of health plan data.
Penson David F, Moul Judd W, Evans Christopher P, Doyle John
J [S], Gandhi Sanjay, Lamerato Lois:
J Urol, 171(6, Part 1 of 2):2250-2254, 2004.
Abstract
10. Predicting risk of prostate specific antigen recurrence
after radical prostatectomy with the Center for Prostate Disease
Research and Cancer of the Prostate Strategic Urologic Research
Endeavor databases.
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC,
Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001.
